{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-004783","form_type":"8-K","ticker":null,"cik":"0000887247","company_name":"DMK PHARMACEUTICALS Corp","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.631283+00:00","generated_at":"2026-06-17T01:42:14.966436+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adamis Pharmaceuticals receives Nasdaq deficiency notice for MVLS below $35M","bullets":["Nasdaq notice on April 12, 2023: Market Value of Listed Securities below $35M for 30 consecutive business days.","Company has until Oct 9, 2023 to regain compliance by achieving MVLS >= $35M for 10 consecutive business days.","If not compliant by deadline, Nasdaq will issue delisting notice; company may appeal.","No immediate impact on listing or trading of common stock (ADMP)."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-004783","json":"https://secwatch.observer/filing/0001387131-23-004783.json","markdown":"https://secwatch.observer/filing/0001387131-23-004783.md","text":"https://secwatch.observer/filing/0001387131-23-004783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887247/000138713123004783/0001387131-23-004783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887247/000138713123004783/admp-8k_041223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:42:14.966436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"033ca5757184e24ad9fcce20b84f0a5416180f68","claim":"DMK PHARMACEUTICALS Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"April 12, 2023, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). The Notice is only a notification of deficiency, not of imminent delisting","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123004783/0001387131-23-004783-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}